AzTrials
AzTrials

Head and Neck CancerNCT05073809

Photoacoustic Imaging of Head and Neck Tumours

An observational study of Head and Neck Cancer, run by University College, London.

Withdrawn

Withdrawn. The study stopped before anyone enrolled.

Official record
Search all trials

Trial summary

Cancer is the commonest cause of death in the UK, and a national and international healthcare priority. Survival in the UK is relatively poor vs. European comparators1, meaning early tumour detection and accurate clinical assessment is particularly important to improve outcomes. Read more about this study

Who is it for?
Ages 18 to 99 years
Conditions the study is for
Head and Neck Cancer
What is being tested?
Photoacoustic Imaging Scan
Type of treatment
Pill or oral medicine
How many people
0 participants
Where
No sites listed yet
Study dates
29 Sep 2022to 29 Sep 2022
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 99 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Head and neck tumours

Who may be able to join

  • Proven or highly suspected to have a head and neck tumour, including oral cavity cancer, and/or abnormal LN in the head and neck (on the basis of physical examination or medical imaging).
  • 18 years or older (no upper age limit).

Who cannot join

  • Unable to provide informed written informed consent (e.g. dementia, significant mental illness, brain metastases).
  • Severe skin or mucosal disease precluding safe, comfortable placement of the US or PAT probes (e.g. active infection; ulcerating tumour).
  • Contraindication to MRI magnetic field e.g. non-MRI compatible pacemaker, cochlear implant, severe claustrophobia, or allergy to MRI contrast agent (Gadolinium)
  • Restricted mouth opening in those patients with an oral cavity neoplasm

About this study

Official title: Clinical Translation of Photoacoustic Imaging for the Assessment of Head and Neck Tumours

Cancer is the commonest cause of death in the UK, and a national and international healthcare priority. Survival in the UK is relatively poor vs. European comparators1, meaning early tumour detection and accurate clinical assessment is particularly important to improve outcomes. Treatment fundamentally depends on tumour staging, both of the local cancer and of draining lymph nodes (LN), as well as distant spread of disease i.e. TNM stage (tumour (T), node (N) and metastases (M). However, current non-invasive pre-operative imaging technologies of ultrasound (US), computed tomography (CT) and magnetic resonance imaging (MRI) are limited in sensitivity and specificity for nodal assessment, either missing disease or subjecting patients to unnecessary additional invasive biopsies or surgery.

A simple, rapid, non-invasive tool to assess primary tumours and LN involvement would be of great clinical value. One candidate technology is photoacoustic tomography (PAT), a relatively novel modality that combines exquisite spatial resolution with the ability to image multiple biological tissues, including blood, water and lipid. To date, PAT has been most successful in imaging the vasculature, which is of particular interest for oncological imaging because one of the key hallmarks of cancer is the development of new, abnormal blood vessels (neoangiogenesis). The high sensitivity for superficial imaging with PAT means that head and neck tumours and neck LN are readily amenable for assessment. In this cohort of patients, those with oral cavity tumours, in particular tumours arising from the lining of the tongue, would be readily accessible for direct scanning.

Read the detailed description

Cancer accounts for almost 30% of all deaths in England and Wales. Head and neck cancer is the 8th most common cancer in the UK, and over the last decade the incidence and mortality rates have increased by 24% and 14% respectively. Squamous cell carcinoma (SCC) or a variant is the commonest histologic type in these cancers. The prognosis and treatment fundamentally depend on the TNM stage. For example, the 1- and 3-year survival rates for patients with early stage oral cavity cancer (Stage 1 and 2) are around 90% and 65%; however, for late stage disease (Stage 3 and 4), this drops to around 80% and 45% respectively. Patients with advanced disease often require more aggressive treatment such as pre-operative (neo-adjuvant) chemotherapy, radiotherapy or both; and usually need more extensive surgery / radiotherapy when definitive treatment is instituted.

The eighth edition of the TNM classification of malignant tumours, which provides internationally agreed-upon standards to stage cancer, now includes the depth of invasion (DOI) of oral cancer for accurate T staging, with 5mm being the cut off between Stages 1 and 2, and 10mm the cut off for Stages 2 and 3 disease. Not only does the precise extent of local growth determine whether or not a limited local resection can be achieved rather than a more radical excision, but the DOI dimension, which is thought to reflect the proximity to underlying lymph and vascular structures, is a good predictor of LN involvement. As described, the survival rate in these patients is related to the stage of the disease therefore imaging is a crucial determinant of prognosis. There is a paucity of data on the reliability of radiologic and clinical staging of DOI as well as the subsequent concordance of these measurements against the pathologic i.e. post-surgical, DOI. The imaging modality used to assess the T stage/DOI of oral cavity cancer varies between US, CT and MRI depending on the preference of the centre. Small studies evaluating how accurate each of these imaging modalities are at determining DOI have been performed with promising results, however they are limited.

Limitations in radiologic and clinical staging of the neck LN are also well known and elective neck dissection (END), which involves resecting the entire regional LN group, is still considered the most accurate diagnostic procedure for N staging. The reported mean incidence of subclinical occult nodal metastasis detected at END in patients with early stage tongue cancer is around 25% - implying these were missed by conventional imaging. However, this is an invasive surgical technique with significant associated morbidity e.g. neuropathic pain and reduced shoulder movement, and there is uncertainty as to whether it provides any meaningful clinical benefit over observation in patients with early stage disease. An alternative to END in radiologic/clinical N0 SCC of the oral cavity is sentinel lymph node biopsy (SNLB), which involves identifying and excising the initial LN(s) to which a primary tumour drains, thereby attempting to limit the surgical dissection. Even so, this still requires a surgical procedure with the associated risks, costs and patient inconvenience, is not widely-available and still misses >15% of diseased nodes.

A rapid and easy-to-use, non-invasive and well-tolerated test that could improve local and regional cancer staging, as well as help to standardize this assessment across centres would therefore be of great clinical value.

Photoacoustic tomography (PAT) is a relatively novel technology that may be able to help address these needs. PAT relies upon the absorption of laser-generated light of specific wavelengths (often in the infra-red spectrum) by intrinsic components of the imaged tissue. Such absorption results in the emission of ultrasound waves, which can be reconstructed into images in a similar manner to conventional ultrasound scanners. By imaging at multiple wavelengths, the tissue distribution of water, lipid and haemoglobin (in red blood cells and therefore blood vessels) can be mapped with extremely high resolution (~100 microns), raising the possibility that PAT can depict the small volume tumour that existing techniques cannot.

Being tested
Photoacoustic Imaging Scan
Medical subject headings
Head and Neck Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Photoacoustic Imaging ScanDiagnostic test

    A relatively novel modality that combines exquisite spatial resolution with the ability to image multiple biological tissues, including blood, water and lipid.

Study groups in NCT05073809
Study groupRoleWhat they receive
Group 1Proven or highly suspected head and neck tumour undergoing routine clinical staging of their neck LN status
Receives: Diagnostic Test: Photoacoustic Imaging Scan
Group 2Proven or suspected oral cavity cancer, amenable to intraoral examination
Receives: Diagnostic Test: Photoacoustic Imaging Scan

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Group 2

    the primary outcome is to identify the proportion of participants with oral cavity cancer in whom DOI can be successfully measured with PAT i.e. technical success. The outcome is to measure the success of the photoacoustic scanner.

    Measured: 3 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Oct 2021
  2. Study start29 Sep 2022
  3. Primary completion29 Sep 2022
  4. Study completion29 Sep 2022

Why it stopped: Research Fellow left Trust.

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Cross-sectional
Enrolment
0 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05073809
Sponsor's protocol ID
123718
Status last verified
Oct 2023
First submitted
15 Oct 2020
Last updated
27 Oct 2023
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Sant M, Allemani C, Santaquilani M, Knijn A, Marchesi F, Capocaccia R; EUROCARE Working Group. EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer. 2009 Apr;45(6):931-91. doi: 10.1016/j.ejca.2008.11.018. Epub 2009 Jan 24.

    PubMed 19171476
  • Abu-Ghanem S, Yehuda M, Carmel NN, Leshno M, Abergel A, Gutfeld O, Fliss DM. Elective Neck Dissection vs Observation in Early-Stage Squamous Cell Carcinoma of the Oral Tongue With No Clinically Apparent Lymph Node Metastasis in the Neck: A Systematic Review and Meta-analysis. JAMA Otolaryngol Head Neck Surg. 2016 Sep 1;142(9):857-65. doi: 10.1001/jamaoto.2016.1281.

    PubMed 27442962
  • Mizrachi A, Migliacci JC, Montero PH, McBride S, Shah JP, Patel SG, Ganly I. Neck recurrence in clinically node-negative oral cancer: 27-year experience at a single institution. Oral Oncol. 2018 Mar;78:94-101. doi: 10.1016/j.oraloncology.2018.01.020. Epub 2018 Feb 20.

    PubMed 29496065

Questions about this trial

What is this clinical trial studying?

An observational study of Head and Neck Cancer, run by University College, London.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: withdrawn, as of the sponsor's last update on 27 Oct 2023. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was withdrawn before enrolling participants, so there are no results.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Group 2 (time frame: 3 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05073809, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Oct 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in